Drug Search Results
More Filters [+]

Robalzotan

Alternative Names: robalzotan
Latest Update: None
Latest Update Note: None

Product Description

Mechanisms of Action: 5-HT1A Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Robalzotan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Irritable Bowel Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2004-000383-27

P2

Completed

Irritable Bowel Syndrome

2005-06-21

Recent News Events

Date

Type

Title